Key Points
This approval marks the first new type of schizophrenia medicine in several decades that reduces the mental illness symptoms without the common..
Todays landmark approval of our first-in-class treatment for schizophrenia marks an important milestone for the community...
After more than 30 years, there is now an entirely new pharmacological approach for schizophrenia one that has the potential to change the treatment paradigm, said Chris Boerner, board chair and CEO of Bristol Myers Squibb..
As we reenter the field of neuropsychiatry, we are dedicated to changing the conversation around serious mental illness, beginning with todays approval for schizophrenia...
Having a variety of treatment options gives patients and healthcare providers the tools to help manage this serious condition, said Gordon Lavigne, CEO of the Schizophrenia & Psychosis Action Alliance..
